PA8548301A1 - Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion - Google Patents

Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion

Info

Publication number
PA8548301A1
PA8548301A1 PA20028548301A PA8548301A PA8548301A1 PA 8548301 A1 PA8548301 A1 PA 8548301A1 PA 20028548301 A PA20028548301 A PA 20028548301A PA 8548301 A PA8548301 A PA 8548301A PA 8548301 A1 PA8548301 A1 PA 8548301A1
Authority
PA
Panama
Prior art keywords
procedure
preparation
pharmaceutical formulation
flavor
masked flavor
Prior art date
Application number
PA20028548301A
Other languages
English (en)
Spanish (es)
Inventor
Philippe Becourt
Josiane Chauvin
Detlev Schwabe
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PA8548301A1 publication Critical patent/PA8548301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PA20028548301A 2001-06-21 2002-06-19 Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion PA8548301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0108157A FR2826274B1 (fr) 2001-06-21 2001-06-21 Formulation pharmaceutique au gout masque et son procede de preparation

Publications (1)

Publication Number Publication Date
PA8548301A1 true PA8548301A1 (es) 2003-09-05

Family

ID=8864587

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028548301A PA8548301A1 (es) 2001-06-21 2002-06-19 Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion

Country Status (41)

Country Link
US (2) US7138138B2 (enExample)
EP (1) EP1401397B1 (enExample)
JP (1) JP4880871B2 (enExample)
CN (1) CN1239149C (enExample)
AP (1) AP1595A (enExample)
AR (1) AR036096A1 (enExample)
AT (1) ATE290366T1 (enExample)
AU (1) AU2002329311B2 (enExample)
BG (1) BG66314B1 (enExample)
BR (1) BRPI0208998A2 (enExample)
CA (1) CA2452239C (enExample)
CO (1) CO5540278A2 (enExample)
CZ (1) CZ299947B6 (enExample)
DE (1) DE60203178T2 (enExample)
EA (1) EA006016B1 (enExample)
EC (1) ECSP034915A (enExample)
ES (1) ES2236574T3 (enExample)
FR (1) FR2826274B1 (enExample)
GT (2) GT200200115A (enExample)
HR (1) HRP20031067B1 (enExample)
HU (1) HUP0400799A3 (enExample)
IL (2) IL159404A0 (enExample)
JO (1) JO2325B1 (enExample)
MA (1) MA27042A1 (enExample)
MX (1) MXPA03011756A (enExample)
MY (1) MY134340A (enExample)
NO (1) NO332258B1 (enExample)
NZ (1) NZ530042A (enExample)
OA (1) OA12635A (enExample)
PA (1) PA8548301A1 (enExample)
PE (1) PE20030201A1 (enExample)
PL (1) PL202090B1 (enExample)
PT (1) PT1401397E (enExample)
SK (1) SK285865B6 (enExample)
SV (1) SV2003001098A (enExample)
TN (1) TNSN03141A1 (enExample)
TW (1) TWI228049B (enExample)
UA (1) UA77960C2 (enExample)
UY (1) UY27341A1 (enExample)
WO (1) WO2003000225A2 (enExample)
ZA (1) ZA200309479B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384921B2 (en) * 2004-02-20 2008-06-10 Enanta Pharmaceuticals, Inc. Polymorphic forms of 6-11 bicyclic ketolide derivatives
GB2419094A (en) 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
FR2882522B1 (fr) * 2005-02-25 2007-04-13 Aventis Pharma Sa Composition pharmaceutique solide comprenant de la telithromycine
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
US20060264386A1 (en) * 2005-05-17 2006-11-23 Rongqi Sun Pharmaceutical formulations of 6-11 bicyclic ketolide derivatives and related macrolides and methods for preparation thereof
US20090011007A1 (en) * 2006-02-03 2009-01-08 Evonik Roehm Gmbh Pharmaceutical Compositions Containing Mixtures of Polymers and Active Agents Poorly Soluble in Water
US20100226979A1 (en) * 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
KR100935893B1 (ko) * 2007-09-11 2010-01-07 국방과학연구소 1,1'-다이메틸-5,5’-바이테트라졸의 합성방법
CN101917850B (zh) 2007-10-25 2016-01-13 森普拉制药公司 大环内酯类抗菌剂的制备方法
US9428635B2 (en) 2008-12-16 2016-08-30 Carlsberg A/S Coating of hydroxylated surfaces by gas phase grafting
CN104470527B (zh) 2012-03-27 2019-05-28 森普拉制药公司 用于施用大环内酯抗生素的肠胃外制剂
DE102012014848A1 (de) * 2012-07-27 2012-10-31 Heilerde-Gesellschaft Luvos Just GmbH & Co. KG Heilerde-Zubereitung
EP3185864A4 (en) * 2014-08-05 2018-03-28 Cempra Pharmaceuticals, Inc. Powder oral suspension formulations of antibacterial agents
US10982177B2 (en) 2017-09-18 2021-04-20 The Clorox Company Cleaning wipes with particular lotion retention and efficacy characteristics
CN114209661B (zh) * 2022-02-21 2022-04-29 北京罗诺强施医药技术研发中心有限公司 呈细粒形式的固体药物组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2930409A1 (de) * 1979-07-26 1981-02-12 Bayer Ag Spruehtrocknung von mikrokapseldispersionen
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
ZA945944B (en) * 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids
AUPN969796A0 (en) * 1996-05-07 1996-05-30 F.H. Faulding & Co. Limited Taste masked liquid suspensions
US6153220A (en) * 1997-10-03 2000-11-28 Elan Corporation, Plc Taste-masked formulations
IN191239B (enExample) * 1999-06-11 2003-10-11 Ranbaxy Lab Ltd
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
DE60135859D1 (de) * 2000-08-22 2008-10-30 Basilea Pharmaceutica Ag Neue macrolide mit antibakterieller wirkung

Also Published As

Publication number Publication date
AP1595A (en) 2006-04-12
EP1401397A2 (fr) 2004-03-31
PL366803A1 (en) 2005-02-07
CN1239149C (zh) 2006-02-01
HUP0400799A3 (en) 2012-08-28
ECSP034915A (es) 2004-02-26
CA2452239A1 (fr) 2003-01-03
EA006016B1 (ru) 2005-08-25
HRP20031067B1 (en) 2011-10-31
DE60203178D1 (de) 2005-04-14
BG108458A (bg) 2005-02-28
CN1529585A (zh) 2004-09-15
UY27341A1 (es) 2003-01-31
HUP0400799A2 (hu) 2004-08-30
PE20030201A1 (es) 2003-03-12
BG66314B1 (bg) 2013-04-30
EP1401397B1 (fr) 2005-03-09
NO20035581D0 (no) 2003-12-15
ES2236574T3 (es) 2005-07-16
US20040142029A1 (en) 2004-07-22
US7138138B2 (en) 2006-11-21
IL159404A0 (en) 2004-06-01
CO5540278A2 (es) 2005-07-29
JP4880871B2 (ja) 2012-02-22
CA2452239C (fr) 2011-07-19
PL202090B1 (pl) 2009-06-30
ZA200309479B (en) 2005-04-26
IL159404A (en) 2007-08-19
MXPA03011756A (es) 2004-07-01
SV2003001098A (es) 2003-03-18
PT1401397E (pt) 2005-05-31
JO2325B1 (en) 2006-06-28
SK15922003A3 (sk) 2004-05-04
CZ20033441A3 (en) 2004-03-17
HK1067558A1 (en) 2005-04-15
NO332258B1 (no) 2012-08-13
TNSN03141A1 (fr) 2005-12-23
HRP20031067A2 (en) 2004-04-30
BRPI0208998A2 (pt) 2017-06-06
DE60203178T2 (de) 2006-01-26
OA12635A (fr) 2006-06-15
US20070014857A1 (en) 2007-01-18
WO2003000225A3 (fr) 2003-03-13
MY134340A (en) 2007-12-31
JP2004534810A (ja) 2004-11-18
GT200200115A (es) 2003-02-27
AP2003002927A0 (en) 2003-12-31
WO2003000225A2 (fr) 2003-01-03
TWI228049B (en) 2005-02-21
EA200400061A1 (ru) 2004-06-24
NZ530042A (en) 2005-09-30
ATE290366T1 (de) 2005-03-15
CZ299947B6 (cs) 2009-01-07
MA27042A1 (fr) 2004-12-20
AR036096A1 (es) 2004-08-11
FR2826274B1 (fr) 2003-09-26
UA77960C2 (en) 2007-02-15
FR2826274A1 (fr) 2002-12-27
AU2002329311B2 (en) 2007-02-01
GT200200115AA (es) 2005-01-12
SK285865B6 (sk) 2007-10-04

Similar Documents

Publication Publication Date Title
PA8548301A1 (es) Formulacion farmaceutica de sabor enmascarado y procedimiento para su preparacion
CL2007003331A1 (es) Metodo para tratar cancer mediante la administracion de un agente radiosensibilizante derivado de benzo[a]trinden-4,6-diona; composicion farmaceutica que comprende dicho agente.
BR0207760A (pt) Composição farmacêutica, uso da mesma, métodos para o tratamento de dor e de inflamação, e, processo para a preparação de uma composição
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
BR0112495A (pt) Forma de dosagem, processo para a produção de uma forma de dosagem e uso da forma de dosagem
ES2167061T3 (es) Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino.
CR10838A (es) Derivados de 2,3-dihidroimidazol [1,2-c] quinazolina sustituidos, de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogenesis
AR087239A2 (es) Formulaciones farmaceuticas solidas que comprenden telmisartan
DE122011100049I1 (de) Stabile pharmazeutische Losungsformulierungen fur unter Druck stehende Inhaliergerate fur die Verabreichung abgemessener Dosen.
WO2012040623A3 (en) Nanostructured gels capable of controlled release of encapsulated agents
MX2009004874A (es) Formulaciones farmaceuticas estratificadas que comprenden una capa intermediaria que se disuelve rapidamente.
WO2003043586A3 (en) Compositions for sustained action product delivery
PA8586201A1 (es) Nuevas formulaciones de liberacion prolongada inyectables
WO2005009357A3 (en) Controlled release compositions
WO2006106514A3 (en) Electrospun dosage form and method of producing the same
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
DOP2002000389A (es) Metodo para fabricar una composición farmaceutica de dosis baja que tiene una distribución y potencia del fármaco uniforme
ECSP066553A (es) Formas de administración masticables, no comprimidas dosificadas individualmente.
IL150528A0 (en) Ibuprofen containing active agent preparation
ES2195573T3 (es) Preparado farmaceutico solido con estructura multifase para administracion oral de gatifloxacina o sus sales o hidratos farmaceuticamente utilizables y procedimiento para su preparacion.
AU2001235783A1 (en) Therapeutic compositions for pulmonary delivery
WO2008087323A8 (fr) Forme galenique pour l'administration par voie trans-muqueuse de paracetamol
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
WO2008051527A3 (en) Sustained release of agents for localized pain management
PA8549401A1 (es) Complejo que comprende factor inhibidor de osteoclastogenesis y polisacarido